Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Sorafenib is approved by both the FDA and EMA for the treatment of differentiated thyroid cancer that is refractory to radioactive iodine (RAI), specifically for locally advanced or metastatic cases. This approval was based on successful phase III clinical trials showing significant improvement in progression-free survival (2, 3, 4)
Several molecularly targeted drugs for treating radioiodine resistant differentiated thyroid carcinomas (RAIR-DTC) have been identified. Among these, sorafenib has been approved for clinical use in many countries (1).